Labcorp (LH)
Health Care · Clinical laboratory services and drug development diagnostics
A global diagnostics and drug development laboratory leader that performs 750+ million clinical tests annually and supports 85% of new FDA-approved drugs through comprehensive testing capabilities.
What Labcorp does
Labcorp is a leading global laboratory services company providing diagnostic testing, drug development support, and laboratory analytics across approximately 100 countries. The company operates through two main segments: Diagnostics (Dx), which delivers clinical laboratory tests to patients, hospitals, and health systems, and Biopharma Laboratory Services (BLS), which supports pharmaceutical companies in drug development and clinical trials. With nearly 71,000 employees, Labcorp serves approximately 175 million patient encounters annually and is a critical partner for healthcare providers, pharmaceutical companies, and consumers seeking diagnostic insights and precision medicine solutions.
Themes: ["Precision medicine and personalized diagnostics","Drug development and clinical trials","Cell and gene therapy","Specialty diagnostics (oncology, women's health, autoimmune, neurology)","Healthcare partnerships and consolidation","Molecular diagnostics and biomarker testing","Consumer health engagement","Global expansion"]
Fundamentals
- Price$277.63 as of 2026-07-09 close
- Market cap$22.8B as of 2026-07-10
- 1-year return+7.2% as of 2026-07-09 close
- P/E24.18 as of 2026-07-10
- Net margin+6.7% as of 2026-07-10
- Gross margin+28.8% as of 2026-07-10
- ROE+10.9% as of 2026-07-10
- Debt / equity0.73 as of 2026-07-10
- Revenue growth (YoY)+7.3% as of 2026-07-10
- Revenue CAGR (3y)+5.6% SEC XBRL
- Beta0.88 as of 2026-07-10
Dividend: yield +1.0%; 4-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Dependence on reimbursement rates and managed care organizations; changes in healthcare policy and insurance coverage could adversely impact volumes and pricing","Significant debt burden from acquisitions and capital structure; rising interest rates increase financing costs and limit financial flexibility","Regulatory and compliance risks including FDA oversight of laboratory developed tests (LDTs), CLIA licensing, and government investigations into billing practices and data privacy"]
Competitors & peers
- Quest Diagnostics (DGX)
- LabCorp Drug Development (spun off as Fortrea Holdings Inc. in June 2023)
- Sonic Healthcare
- Charles River Laboratories (CRL)
- Syneos Health
- Clinical Laboratory Partners
- Hospital-based laboratory networks
- Integrated health system laboratory operations
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.